Company intelligence / Profile preview

ResolutionRx Ltd

Ownership: Private
Development stage: Phase 2

Overview

Two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms and quantitative measures of obstructive sleep apnea. The company is preparing for a pharmacokinetic study with a new formulation followed by Phase 3 international clinical trials[2][3].

Therapeutic areas: PulmonologyOncologyInfectious Diseases
Modalities: Cannabinoidsdronabinol (synthetic cannabinoid)
Industry: Biotech

Drug pipeline

2 assets

dronabinol

Phase 2

Indications: Obstructive sleep apnea

1 more asset in the full pipeline.

Request access →

Partnerships

iNGENu (CRO)Radium Capital (financing)

Beyond the preview

Go deeper on ResolutionRx Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ResolutionRx Ltd.

Explore the full profile